Rachida Siham Bel Aiba

This inventor holds 19 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Pieris Pharmaceuticals Gmbh, Daiichi Sankyo Company, Limited, Pieris Ag. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rachida Siham Bel Aiba. Retrieved from https://idiyas.com/inventor/rachida-siham-bel-aiba

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 9)

% Patents Active = 63.2

CIPO Patents = 2 (Patent Applications = 12)

EPO Patents = 6 (Patent Applications = 18)

Average Co-Inventor Count = 7.0

ph-index = 3

Forward Citations = 41(Granted Patents)

Company Filing History:

15 out of 37

Pieris Pharmaceuticals Gmbh

patents

2 out of 463

Daiichi Sankyo Company, Limited

4. 1 out of 834,570

Other

patents

Years Active: 2015-2025

Loading Chart...

Areas of Expertise:

Fusion Proteins

CD137

GPC3

Lipocalin Muteins

Anti-Cancer

Nucleic Acid Molecules

Immune Response

Angiopoietin-2

Neutrophil Gelatinase

LAG-3

Calcitonin Gene-Related Peptide

PCSK9

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12486330 - Novel Fusion Proteins Specific for CD137 and GPC3 (2025-12-02),

2. 12195503 - Proteins specific for CD137 (2025-01-14),

3. 11919931 - Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3) (2024-03-05),

4. 11773147 - Lipocalin muteins with binding affinity for LAG-3 (2023-10-03),

5. 11261221 - Proteins specific for CD137 (2022-03-01),

6. 11168119 - Lipocalin muteins with binding affinity for LAG-3 (2021-11-09),

7. 11034738 - Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2) (2021-06-15),

8. 11034737 - Proteins specific for calcitonin gene-related peptide (2021-06-15),

9. 10927156 - Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune response (2021-02-23),

10. 10913778 - Anti-cancer fusion polypeptides, encoding nucleic acids and methods of using polypeptides (2021-02-09),

11. 10865250 - Anti-cancer fusion polypeptide (2020-12-15),

12. 10787491 - Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) (2020-09-29),

13. 10526382 - Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof (2020-01-07),

14. 10501510 - Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof (2019-12-10),

15. 10400016 - Proteins specific for calcitonin gene-related peptide (2019-09-03),

Title: Rachida Siham Bel Aiba: Innovator in Cancer Therapeutics

Introduction

Rachida Siham Bel Aiba is a prolific inventor based in Munich, Germany, with an impressive portfolio of 18 patents focusing on innovative therapeutic approaches in the field of oncology. Her work has significantly contributed to the development of novel proteins and polypeptides that hold promise for the treatment and prevention of various human diseases, including cancer.

Latest Patents

Among her latest patents is a remarkable invention concerning "Proteins Specific for CD137." This disclosure reveals human lipocalin muteins that bind CD137 and have potential applications in pharmaceuticals as anti-cancer agents and immune modulators. Additionally, the invention discusses methods for creating these lipocalin muteins, along with nucleic acid molecules encoding them and compositions containing these muteins for therapeutic and diagnostic uses.

Another notable patent is the "Anti-cancer Fusion Polypeptide Capable of Binding Both CD137 and Glypican-3 (GPC3)." This fusion polypeptide can effectively direct CD137 clustering and activation toward GPC3-positive tumor cells, presenting a promising avenue for anti-cancer therapies. The disclosure also explores methods for its production and therapeutic applications, showcasing the innovative nature of Bel Aiba's work.

Career Highlights

Rachida has built her career in esteemed organizations, including Pieris Pharmaceuticals GmbH and Daiichi Sankyo Company, Limited. Through her dedication and expertise, she has established herself as a key figure in the development of advanced therapeutic solutions in the life sciences sector.

Collaborations

Throughout her career, Rachida has collaborated with talented professionals like Christine Rothe and Andrea Allersdorfer. These collaborations reflect her commitment to fostering innovative research and her ability to work effectively within multidisciplinary teams, aiming to advance cancer treatment methodologies.

Conclusion

Rachida Siham Bel Aiba's pioneering contributions to the field of oncology, exemplified by her numerous patents and collaborative efforts, underscore her status as a significant inventor in the biopharmaceutical industry. Her innovative approaches to developing CD137-targeting therapies highlight the potential of her inventions to transform cancer treatment and improve patient outcomes.

Profile summary based on public USPTO records.